SAN DIEGO, March 16, 2010 (GLOBE NEWSWIRE) -- OccuLogix, Inc., dba TearLab Corporation ("TearLab") (Nasdaq:TEAR) (TSX:TLB) announced today that Paul M. Karpecki, OD, FAAO has been appointed to its Board of Directors.
Dr. Karpecki is currently on staff at the Koffler Vision Group in Cornea services and Ocular Disease Research. In addition, he is the Chair of the Refractive Surgery Advisory Board to the American Optometric Association ("AOA"), Co-Chair of the American Society of Cataract and Refractive Surgery Task Force on the Integrated Eyecare Delivery System and serves on the AOA Congress Education Committee.
A noted educator and author on ocular surface disease, Dr. Karpecki presently serves on eight professional journal editorial boards. He has lectured in over 400 symposia covering four continents and was invited to participate in both the Delphi International Society at Wilmer- John's Hopkins that includes the top 25 Dry Eye Disease ("DED") experts in the world, and the National Eye Institute's DED committee.
"We are delighted to have a Dry Eye Disease clinician and researcher of Dr. Karpecki's caliber join the Company's Board," stated Elias Vamvakas, TearLab's Chief Executive Officer. "Paul's scientific accomplishments, in addition to his experience on the Boards of various professional associations, will be a tremendous asset to the Company as awareness and acceptance of the TearLab Osmolarity System™ by eye care practitioners continues to grow globally."
About The TearLab™ Osmolarity System
The TearLab™ Osmolarity System uses a novel lab-on-a-chip approach that requires less than 50 nL (nanoliters) of tear fluid in order to measure tear Osmolarity. The TearLab™ Osmolarity System eliminates the challenges that previously prevented point-of-care Osmolarity testing. The TearLab™ System can produce a sample-to-answer result in less than 30 seconds.
About Dry Eye Disease (DED)
DED is a common condition in which the eye does not produce enough tears to keep the surface of the eye sufficiently lubricated. It affects approximately 40 million people in the US and 100 million people worldwide. In its mild to moderate forms, it can impact vision and the ability to go about daily activities. In its more severe forms, DED can lead to permanent loss of vision.
About OccuLogix, Inc. dba TearLab Corporation
OccuLogix, Inc. dba TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Forward-Looking Statements
This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.